Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00222144 · ClinicalTrials.gov registry record · Phase 2
Study of Gleevec and Taxotere in Recurrent Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by University of Kansas.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT00222144: Completed Phase 2 study, sponsored by University of Kansas.
NCT00222144 is a Phase 2 study that has completed, run by University of Kansas. The registered enrollment target is 23 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00222144, a Phase 2 study, has completed, sponsored by University of Kansas.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
The primary goal of this study is to determine the effects of the combination of Gleevec and Taxotere in lung cancer in terms of control and reduction of the cancer size. The study will also test lung cancer to see if the presence of certain protein called receptor for platelet derived growth factor can influence the effect of the treatment.
Interventions
- DRUG Gleevec and Taxotere
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2004-09 |
| Est. Completion | 2010-11 |
| Phase | Phase 2 |
What the finished NCT00222144 record still lists
NCT00222144 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 1 intervention - of which Gleevec and Taxotere is the first listed.
NCT00222144 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00222144 about?
NCT00222144 is a clinical study titled "Study of Gleevec and Taxotere in Recurrent Non-Small Cell Lung Cancer". The primary goal of this study is to determine the effects of the combination of Gleevec and Taxotere in lung cancer in terms of control and reduction of the cancer size. The study will also test lung cancer to see if the presence of certain protein called receptor for platelet derived growth factor...
What is the current status of trial NCT00222144?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2004-09. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00222144?
The interventions under investigation include: Gleevec and Taxotere (DRUG).
Who is sponsoring clinical trial NCT00222144?
This trial is sponsored by University of Kansas, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00222144's enrollment target sits among peer trials
23 1784th of 2000 higher than 211 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia